WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
11 March 2020
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology
04 March 2020
BioMotiv and Bristol-Myers Squibb announce the launch of Anteros Pharmaceuticals
04 February 2020
U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
17 January 2020
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy
07 January 2020
Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company
21 November 2019
Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals
15 November 2019
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT
31 October 2019
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
18 October 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement
18 July 2019
Bristol-Myers Squibb provides update on pending merger with Celgene
24 June 2019
Bristol-Myers Squibb announces post-closing leadership team
05 June 2019
Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today
16 May 2019
Bristol-Myers Squibb reports first quarter financial results
25 April 2019
Bristol-Myers Squibb shareholders approve Celgene acquisition
12 April 2019
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
15 January 2019
Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma company
03 January 2019
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance
17 December 2018
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to ReviveMed, Strand Therapeutics
26 November 2018
Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors
11 October 2018
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
Amgen successfully completes acquisition of Five Prime Therapeutics
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Research & Development
Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
Patients who are obese or overweight are at risk for a more severe course of COVID-19
New COVID-19 vaccine may offer broad protection from coronaviruses
SARS-CoV-2: New findings on the persistence of neutralizing antibodies
Massive fragment screen points way to new SARS-CoV-2 inhibitors
B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
COVID-19 causes 'unexpected' cellular response in the lungs
Conferences & Events
Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
CPhI Worldwide to return in 2021
Reuters Events' Cell & Gene Therapy USA
Total health: Build a better healthcare system
Don't fall for the 'next best action' trap
Locking down shape-shifting spike protein aids development of COVID-19 vaccine
COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
You are here:
Home
Bristol-Myers Squibb